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Abstract 
Aim - To train and individually validate a group of breast pathologists in specialty specific digital 
primary diagnosis using a novel protocol endorsed by the Royal College of Pathologists' new 
guideline for digital pathology. The protocol allows early exposure to live digital reporting, in a risk 
mitigated environment, and focusses on patient safety and professional development. 
Methods and Results - 3 specialty breast pathologist completed training in use of a digital 
microscopy system, and were exposed to a training set of 20 challenging cases, designed to help 
them identify personal digital diagnostic pitfalls. Following this, the 3 pathologists viewed a total 
of 694 live, entire breast cases. All primary diagnoses were made on digital slides, with immediate 
glass review and reconciliation before final case sign out. There was complete clinical concordance 
between the glass and digital impression of the case in 98.8% of cases. Only 1.2% of cases had a 
clinically significant difference in diagnosis/prognosis on glass and digital slide reads. All 
pathologists elected to continue using the digital microscope as standard for breast 
histopathology specimens, with deferral to glass for a limited number of clinical/histological 
scenarios as a safety net. 
Conclusion - Individual training and validation for digital primary diagnosis allows pathologists to 
develop competence and confidence in their digital diagnostic skills, and aids safe and responsible 
transition from the light microscope to the digital microscope. 
 
Key words 
Digital pathology, validation, training 
 
1. Introduction 
1.1 Digital Pathology 
Digital pathology can be defined as the use of a whole slide imaging (WSI) system to capture, 
transmit and store digital images of glass slides, to be viewed on a computer screen. Digital slides 
can be read by multiple examiners in multiple locations, facilitating remote consultations, 
streamlining workflows and reducing time and financial costs of transferring glass slides between 
locations.  Instantaneous access to multiple users renders digital slide technology invaluable in a 
number of pathology applications including quality assurance programmes, frozen section diagnosis, 
multidisciplinary team meetings, clinicopathological conferences, expert panel/consensus boards 
and education. 
1.2 Digital Pathology in Primary Diagnosis 
Interest in the use of digital pathology for the primary diagnosis of histological specimens is 
flourishing, with a number of laboratories using digital images for primary diagnosis in at least a 
proportion of cases. (eg. Utrecht, Netherlands
1
, Linkoping, Sweden
2
, Leeds Teaching Hospitals NHS 
Trust and Coventry in the United Kingdom
3
). For digital pathology to be accepted and adopted on a 
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large scale, regulatory bodies, diagnostic departments, and individual pathologists will have to be 
convinced that a diagnosis made by a particular pathologist on a digital microscope is as good as a 
diagnosis made by the same pathologist on a conventional light microscope, and that no systematic 
error is introduced into the diagnostic process as a result of the technology.  A recent systematic 
review of the diagnostic concordance of whole slide imaging and conventional light microscopy 
analysed data from 38 concordance studies demonstrated a mean diagnostic concordance of WSI 
and light microscopy (LM) of 92.4%
4
. In comparison, concordance between repeat light microscopy 
reads of the same case was 93.4% in those studies (n=10) that quoted it.   There was a trend for 
increasing concordance in the more recent studies.  The review found evidence to support a high 
level of diagnostic concordance for WSI overall. A recent systematic analysis of instances of 
diagnostic discordance in glass:digital comparisons of the same slides found  335 instances of 
diagnostic discordance, out of 8069 documented instances of a glass diagnosis being compared with 
a digital diagnosis (4%)
5
.  The majority of these discordances would have had no clinical significance, 
and reflected diagnostic scenarios prone to intra- and inter-observer variation in diagnosis, 
regardless of the diagnostic medium used. Potential pitfalls of digital diagnosis were identified, 
including the detection and grading of dysplasia, and the location of small diagnostic or prognostic 
objects including micrometastases. 
1.3 Digital pathology validation 
There is little guidance available to the clinical pathologist on how to validate digital pathology for 
use for primary diagnosis in a real world setting. The College of American Pathologists published a 
guideline for digital pathology validation in 2013
6
, which has formed the foundation of the majority 
of validation studies to date. The guidelines recommend that all departments adopting WSI for 
diagnosis should conduct their own validation, that at least 60 specimens should be evaluated, to 
assess intraobserver variation in diagnosis on digital and glass, with a washout period of at least 2 
weeks between digital and glass reads of cases. Whilst this methodology provides a good baseline 
validation of a departmental whole slide imaging system, it may not be enough to convince the 
individual histopathologist that they are competent and confident to make primary diagnoses on the 
digital microscope.  
1.3 Digital pathology in breast pathology 
Digital slides are used in the undergraduate and postgraduate medical education, with breast 
histopathology images accessible online at sites including the online atlas for breast pathology 
(www2.webmicroscope.net) and the virtual microscopy website of the University of Leeds 
(www.virtualpathology.leeds.ac.uk). In research, digital slides allow for simplified centralised review 
of breast cancer material in large multicentre studies, an option explored by the Prospective Study 
of Outcomes in Sporadic versus Hereditary breast cancer (POSH) cohort study, amongst many 
others.7In the LORIS trial, which aims to address the overtreatment of screen detected ductal 
carcinoma in situ, trial entry depends on real time review of digital slides rather than glass slides to 
assess eligibility. 8 
In clinical pathology, breast pathologists are under increasing pressures in terms of breast cancer 
case volume, case complexity, and the need for rapid evaluation and review to meet cancer 
diagnostic and therapeutic targets. A number of digital pathology validation studies have focused on 
the use of whole slide images for the diagnosis of breast biopsies. Al Janabi et al demonstrated a 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
93% concordance rate in a single reader study of 100 breast biopsies
9
, whilst Campbell et al found 
intraobserver concordance between digital and glass diagnosis of 85 breast biopsies for 3 
pathologists was 95.4%
10
. Both studies identified discordant diagnoses regarding a select group of 
diagnoses: differentiation between hyperplasia and atypical ductal hyperplasia (ADH), the 
differentiation of benign phyllodes tumours from fibroadenomas, and the identification of foci of 
microinvasion/lymphovascular invasion. In their validation study, Reyes et al found digital:glass 
variation in diagnosis varied between 1% and 4% for their 3 pathologists, and in all cases of 
discordance, the diagnostic issue was the differentiation of ductal hyperplasia from atypical 
hyperplasia. 
11
 
The majority of breast digital pathology validation studies in the literature focus on biopsy 
specimens, whilst in real practice, a large proportion of the pathologists time is spent viewing 
resection specimens, where a checklist of histological parameters of an excised tumour need to be 
assessed and recorded. Shaw et al published their experience reviewing both glass and digital slides 
of breast cancers from the POSH breast cancer cohort study
7
.  9 pathologists collected data items 
from digital slides of breast tumours, and then reviewed the glass slides at a later date.  Diagnostic 
performance with the digital slides was comparable to conventional light microscopy. There was 
better agreement on degree of tubule formation between different reviewers using digital slides 
than glass slides. The authors suggest that this supports the assertion that the whole slide view 
provided in digital pathology permits superior assessment of the architecture of a lesion compared 
with light microscopy.   A recent non-inferiority study compared reads of 299 breast cases by 4 
pathologists, and found no significant difference in the incidence of major discordances using digital 
microscopy versus light microscopy.
12
 
 
Leeds Teaching Hospitals NHS Trust made the decision to pilot digital pathology for the primary 
diagnosis of breast histopathology specimens, utilising a novel validation protocol which offered 
participant histopathologists digital microscopy training, exposure to challenging cases, and a risk 
mitigated early conversion to a full digital slide workload.  
 
2. Methods 
The study was performed in the histopathology department of St James University Hospital, Leeds, 
United Kingdom, a large academic institution with full histopathologist subspecialisation, which 
processes in the region of 250,000 H&E stained histology slides per annum. 3 consultant breast 
histopathologists with 35 years of combined practice were recruited to participate in the validation 
study. Scanning of all breast histopathology glass slides prior to laboratory send out was initiated in 
August 2016. Scanning was performed using a single Aperio AT2 scanner for standard dimension 
slides (Leica Aperio, Vista, US), and a single CS2 scanner (Leica Aperio, Vista, US) for large slides. 
Standard slides were scanned at 40x equivalent magnification, and large slides at 20x equivalent 
magnification. Automated scanning processes (selection of scanning area, placement of focus 
points) were quality checked and repeated manually by a laboratory technician where necessary. 
Digital images were stored in a remote digital archive, along with relevant clinical information, 
including a scanned copy of the original request form, and retrieved using e-Slide Manager software 
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(Leica Aperio, Vista, US).   Images were viewed by consultant pathologists using Leeds Virtual 
Microscope viewing software (University of Leeds, Leeds TH NHS Trust
13
) on medical grade Coronis 
Fusion 6 MP, 30.40 inch screens (Barco, Kortrijk, Belgium). 
The validation protocol is published as an appendix to the Royal College of Pathologists Guidelines 
for Digital Pathology, where it is cited as an example of best practice. The validation structure 
consisted of 3 phases, a training phase (T), a validation training set phase (V1), a live reporting 
validation phase (V2) and a summary phase (S). (See table 1 for an overview of validation 
procedure). Prior to the initiation of training, each participant completed a questionnaire detailing 
their prior experience of, and attitude towards digital pathology.   
2.1 Training Phase (T1) 
In T1, each participant received a one hour individual session in basic use of the digital pathology 
slide viewer (LVM), and the image management software (e-Slide Manager), and was issued a user 
manual. Participants were observed opening and evaluating cases, and given feedback regarding 
effective use of input modalities (mouse and keyboard shortcuts). The participant could request 
additional training as required.     
2.2 Validation 1 ʹ Training set (V1) 
In V1, each participant received a training set of 20 cases, in glass slide and digital slide formats. The 
training set was designed to encompass the breadth of breast diagnosis, and confront the 
participant with cases which might be challenging to diagnose digitally. The cases were chosen based 
on clinical relevance to our department, and the challenging digital cases were selected based on a 
review of the literature concerning digital discordance
5
. (See table 2). Participants viewed the 
training set in their own time. For each case, the digital slides were viewed first, then the pathologist 
recorded their diagnosis, and their level of confidence in their diagnosis, on a Likert scale from 1-7, 
where 1 corresponded to no not at all confident, and 7 to very confident.  
The pathologist then viewed the glass slides for the same case, immediately after the digital read, 
and recorded any alteration in their diagnosis, and their confidence in their glass slide diagnosis. 
When all participants had completed the training set, the results were discussed in a group with the 
validator, and all participants reviewed discordant cases on glass and digital slides. Pathologists 
identified the types of case they found problematic on digital, so that they could ensure they were 
vigilant for these type of error in the next phase, V2. 
2.3 Validation 2 ʹ Live cases (V2) 
In V2, the totality of each participants breast pathology workload was scanned prospectively. The 
pathologists made their primary diagnosis on digital slides, recording it in a spreadsheet, along with 
their confidence in their diagnosis. All cases were then checked on glass before final reporting, and 
any modification to the diagnosis was recorded, along with the glass slide confidence in diagnosis, 
and the preferred diagnostic medium for each case. Pathologists were also asked to record any 
technical failures  ? ie. out of focus digital slides, or those with any digital artefact which might 
preclude confident or safe diagnosis.  
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All discordances were discussed at weekly to fortnightly validation meetings, were digital and glass 
slides were reviewed by all available participants and the validator.  
When each participant had viewed 2 months whole time equivalent workload (estimated at 
approximately 200 cases based on departmental data),  their diagnostic spreadsheets were analysed 
by the validator, and concordance and discordance data was summarised.  This data was discussed 
between each participant and the validator, and the scope of that pathologists future digital 
pathology practice was agreed upon, with specific criteria documented for cases which require a 
check on glass before final sign out.  
3. Results 
3.1 Validation 1 ʹ Training set (V1) 
Each participant viewed the same 20 training cases on digital slides and glass, consisting of 60 slides 
in total. Mean diagnostic concordance for all participants was 92% (range 80% - 100%). Discordant 
cases concerned the following areas of diagnosis: mitotic count component of invasive tumour 
grading, failure to detect weddelite calcification, micrometastasis detection, and the recognition of 
ductal atypia. 
3.2 Validation 2 ʹ Live cases (V2) 
The participants viewed a total of 694 complete breast histopathology cases, consisting of 15,000 
slides. The cases were representative of the specimen type and diagnostic category mix found in the 
departmental breast workload. (See tables 3 and 4). 
In the course of the validation, a technical failure rate of 1.0% was observed - these were cases 
where scanning artefact or focus issues with digital slides resulted in the pathologist rejecting the 
digital slides and making a diagnosis on glass. There was complete clinical concordance between the 
glass and digital impression of the case in 98.8% of cases. Only 1.2% of cases had a clinically 
significant difference in diagnosis/prognosis on glass and digital slides. (See table 5) 
All discordances were reviewed on glass and digital by the validation group and trainer. Clinically 
significant discordances concerned the mitotic count component of invasive tumour grading, 
identification of weddelite calcification, identification of isolated tumour cells, assessment of a 
fibroepithelial lesion for cellularity, and identification of focal epithelial atypia. (See figure 1 for 
example images). The 2 most significant discordances both concerned the diagnosis of DCIS. In one 
case, a small focus of DCIS was missed on the digital read of an otherwise B3 screening case, whilst 
in another case, a small focus of DCIS was correctly diagnosed on the digital slide in a large, multi-
slide case, but missed on the initial glass review of the case. The pathologist had to revert to the 
digital case to locate the corresponding glass slide, and was then able to identify the DCIS on the 
glass, which had been overlooked. Use of glass slides only for this case could have resulted in 
misclassification of a B5a case as B2. (See table 6). 
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3.3 Diagnostic confidence and diagnostic modality preference 
Mean diagnostic confidence (on a Likert scale from 0-7) was similar for each pathologist for digital 
slides and for glass slides. (See table 7), although the range of diagnostic confidence scores was 
dramatically different for one pathologist (0-7 on digital, versus 6-7 on glass). 
All of the participant pathologists identified a proportion of cases for which they preferred to use 
glass slides over digital slides, although digital slides were judged to be superior or equivalent to 
glass slides in the vast majority of cases. (See figure 2). Cases where glass slides were preferred all 
involved mitotic counting, weddelite detection and lymph node searches. 
3.4 Beliefs about digital pathology efficiency 
Prior to their validation procedure, the pathologist group predicted that viewing digital slides would 
be slightly slower than viewing glass slides, and that breast resections would be much slower to 
report on digital.   After the validation procedure, the pathologists reported that they perceived their 
digital reads of resection cases and large/multi-level biopsies to be much faster using digital slides 
rather than glass slides, and resections to be either slightly faster or much faster on the digital 
microscope.  
Prior to the validation procedure, pathologists believed the most relevant barriers to digital 
pathology adoption were increased time to view digital slides compared with glass slides, 
ƉĂƚŚŽůŽŐŝƐƚƐůĂĐŬŽĨĞǆƉŽƐƵƌĞƚŽĚŝŐŝƚĂůƉĂƚŚŽůŽŐǇĂŶĚƉĂƚŚŽůŽŐŝƐƚƐ ?ƌĞƐŝƐƚĂŶĐĞƚŽĐŚĂŶŐĞ ?&ŽůůŽǁŝŶŐ
the validation procedure they identified the chief barriers to digital pathology adoption were 
financial cost to the department and the time taken to scan slides in the laboratory. 
When asked to list the principal benefits of digital slides over glass slides, pathologists listed ease of 
access to previous biopsies/linked specimens, more efficient diagnosis of large cases/multi slide 
biopsies, diagnostic utility of the low power overview of the slide, more efficient delivery of digital 
slides to the pathologists desktop, enhanced opportunities to teach trainees and ergonomic 
benefits. 
4. Discussion 
Digital pathology has the potential to transform the way in which breast pathology services are 
delivered. Rapid transfer of images across geographical boundaries can allow for more efficient 
dispersal of pathology workload between linked hospitals, and make best use of pathologist 
manpower. Rapid access to second opinion on challenging cases, and increased collaboration 
between pathologists on cases could lead to significant improvements in the quality of pathology 
diagnosis.  
Successful adoption of digital pathology for primary diagnosis in a department is dependent on 
individual pathologists, many with decades of experience reporting on a light microscope, engaging 
with a new technology, educating themselves on its limitations, and actively learning how to use 
software and hardware efficiently.  As with the adoption of any new diagnostic procedure, patient 
safety should be paramount. The US Food and Drugs Administration guidance to manufacturers 
recommends that medical devices (including whole slide imaging systems) should be able to 
demonstrate established safety and effectiveness
14
. The new digital pathology guidelines published 
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by the Royal College of Pathologists also describe the need for individual pathologists to be validated 
with sufficient rigour to satisfy an internal or external observer that safety and clinical effectiveness 
are maintained. The document also emphasises that validation should occur in a real world context. 
This study documents the first instance of use of the novel validation and training protocol for digital 
primary diagnosis of histological specimens recommended as an example of best practice in the 
ZŽǇĂů ŽůůĞŐĞ ŽĨ WĂƚŚŽůŽŐŝƐƚ ?Ɛ 'ƵŝĚĞůŝŶĞƐ ĨŽƌ ŝŐŝƚĂů WĂƚŚŽůŽŐǇ  ? ? ? ? ? ? ?The philosophy of this 
validation protocol differs greatly from the approach of the College of American Pathologists 
Guideline
6
 and of other non-inferiority studies.  Firstly, it is centred on the individual pathologist 
rather than a department as a whole, and secondly it is competence driven rather target driven. This 
approach takes into account the variability in IT competencies, diagnostic experience and 
enthusiasm for technology between pathologists, and allows all members of a department, whether 
enthusiasts or skeptics to develop digital pathology skills and gain confidence in their abilities. Three 
ƐƉĞĐŝĂůŝƐƚďƌĞĂƐƚƉĂƚŚŽůŽŐŝƐƚƐǀŝĞǁĞĚ ? ? ?ĐŽŵƉůĞƚĞ ?ůŝǀĞ ?ďƌĞĂƐƚĐĂƐĞƐ ?ŝŶĐůƵĚŝŶŐůĂƌŐĞĨŽƌŵĂƚƐůŝĚĞƐ ?
stained with haematoxylin and eosin, immunohistochemistry and special stains. Complete clinically 
significant concordance was observed in 98.8% of cases, indicating excellent agreement between 
digital primary diagnosis and glass slide review. Our findings suggest that pathologists, given access 
to digital pathology training, and a risk mitigated diagnostic environment to gain real world digital 
reporting experience, can competently and confidently use digital pathology for primary diagnosis as 
standard practice.  
The training and validation process allowed the participant pathologists to identify and discuss areas 
of digital diagnosis they found more challenging, and identify subtypes of breast case which warrant 
glass review of digital slides, in order to maintain patient safety and allow for further education of 
the pathologist and navigation of specific learning curves (eg. for confident identification of mitotic 
figures or navigation of lymph nodes). Identification and counting of mitotic figures was consistently 
highlighted as an area of difficulty for pathologists. Our pathologists perceived two causes of this 
difficulty in digital reporting: firstly they suggested that less contrast between chromatin and the 
background on digital slides made mitoses harder to identify, and secondly, they were unable to 
fine-focus on suspected mitotic figures on digital slides, a function they often perform on glass slides 
to confirm the identity of mitoses. A number of workarounds and strategies to mitigate this difficulty 
could be considered, including use of immunohistochemistry to highlight mitoses, the use of image 
analysis software to automate mitotic counts, or mandatory checks of mitotic count on glass slides 
prior to specimen sign out, in cases where mitotic score would affect overall grading of an invasive 
tumour.  
Our pathologists reported perceived greater efficiency in reporting multi-slide biopsies and large 
resections on digital slides, which they attributed to a number of factors. This was partly because 
they no longer had to load and reload glass slides on the microscope stage, and could move swiftly 
between slides. In addition, they found the full screen low power view of individual slides enabled 
them to assess lesional architecture with greater ease, and they were able to make measurements 
using digital tools efficiently and accurately. The relative diagnostic efficiency of pathologists using 
digital versus glass slides deserves further attention, especially now that we have a growing cohort 
of pathologists with significant digital microscopy experience to compare fairly with conventional 
light microscopy . Others benefits of digital reporting noted by our pathologists included rapid access 
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to previous biopsy specimens when reviewing resections, more engaging education and training of 
junior colleagues, and ergonomic benefits. 
As a consequence of this validation study, our validated breast pathologists now report all cases on 
digital slides as standard, reverting to glass following digital examination only for cases fulfilling set 
criteria (invasive cancers where differences in mitotic score could affect overall grade, cellular 
fibroepithelial lesions, cases with radiological confirmation of calcification but no calcium identified 
on digital, and any challenging case not encountered in the validation phase.) Next year, the 
laboratory at Leeds Teaching Hospitals NHS Trust will commence scanning all histopathology slides 
for all specialties, and all consultants will complete a validation procedure for the relevant diagnostic 
subspecialty. As the validation process is completed for each specialty, we will gather more data on 
challenging areas of digital diagnosis.  It is important that individual departments share their 
experiences with digital pathology, and highlight areas of potential difficulty which can be prioritised 
in the digital training of their colleagues to ensure a safe transition from glass slide to digital slide 
reporting. 
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Figures legends 
Figure 1. Examples of discordant validation cases 
Clockwise from top left. Missed micrometastasis in a sentinel lymph node, Difficulty identifying 
mitotic figures, Missed weddelite calcification, Cellularity of stroma overcalled 
 
Figure 2. Diagnostic preferences of individual pathologists 
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Table 1. Summary of validation phases 
Phase Overview 
Training (T) 1:1 formalized training in digital microscope use. 
Observed practice with feedback. 
Validation  ? Training Cases (V1) Training set of 20 challenging and informative 
specialty specific cases. 
Participant views digital slides, make notes on 
diagnosis, immediately checks corresponding 
glass slides and notes any difference in opinion. 
Group discussion. 
Identify and mitigate pitfalls. 
Validation  ? Live reporting (V2) All cases scanned prospectively. 
Diagnosis made on digital slides with 
reconciliation with glass slides before sign out. 
Difficulties recorded and discussed. 
Library of problematic cases assembled and 
reviewed with group. 
Summary and recommendations (S) Validation document produced with each 
pathologist, documenting 
concordance/discordance. 
Recommendations made for scope of digital 
practice / further training. 
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Table 2. Validation Training Case Set 
Case Diagnosis Domains explored 
1 Benign phyllodes tumour Diagnosis (benign fibroepithelial) 
2 Fibrocystic change, weddelite calcification Diagnosis (benign tissue), Identification of weddelite 
calcification 
3 Fat necrosis Diagnosis (benign/inflammatory condition) 
4 Sparse residual ductal carcinoma, post 
chemotherapy 
Diagnosis (malignant epithelial), Grading,  
Immunohistochemistry interpretation (sparse tumour 
cells) 
 
5 Invasive ductal carcinoma, grade 2, 
neuroendocrine features  
Diagnosis (malignant epithelial), Grading, 
Immunohistochemistry interpretation, Identification of 
neuroendocrine features. 
 
6 High grade DCIS with small, grade 1 invasive 
component 
Diagnosis (malignant epithelial), Grading, 
Identification of small invasive component 
7 Atypical ductal hyperplasia, flat epithelial 
atypia, microcalcification, sclerosed papilloma 
 
Diagnosis (benign and atypical epithelium, papillary 
lesion), Identification of microcalcification 
 
8 Invasive ductal carcinoma, grade 3 Diagnosis (malignant epithelial), Grading, 
Immunohistochemistry interpretation 
 
9 3DJHW¶VGLVHDVHRIQLSSOH Diagnosis (malignant epithelium) 
Immunohistochemistry/special stain interpretation 
 
10 Fibroadenoma with ductal carcinoma in situ 
 
Dual diagnosis (malignant epithelium and 
fibroepithelial lesion) 
 
11 High grade ductal carcinoma in situ, no 
calcification 
Diagnosis (malignant epithelium),  Grading,  
Identification that no microcalcification is present 
 
12 Benign sclerotic lesion Diagnosis (benign lesion) Immunohistochemistry 
interpretation 
 
13 5mm lymph node metastasis Diagnosis (locate metastasis) 
 
14 Organising haematoma 
 
Diagnosis (benign/inflammatory) 
 
15 Apocrine metaplasia with atypia 
 
Diagnosis (borderline lesion) 
 
16 Lymph node with micrometastasis Diagnosis (locate micrometastasis) 
 
17 Nipple dermatitis Diagnosis (benign dermatosis) 
 
18 Mucinous carcinoma, grade 1 Diagnosis (malignant epithelial), Grading, Identification 
of mucin 
 
19 Pleomorphic lobular carcinoma, grade 2 Diagnosis (malignant epithelial), Grading, Identification 
of pleomorphic lobular component 
 
20 Invasive lobular carcinoma, grade 2 
 
Diagnosis (malignant epithelail), Grading, Identification 
of classical lobular features 
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Table 3. Case Mix by Specimen Type 
Specimen type Number of cases 
Vacuum assisted biopsy 159 
Core biopsy 397 
Wide local excision 28 
Mastectomy 27 
Other excision 55 
Immuno/special stains 28 
Total 694 
 
 
Table 4. Case Mix by Diagnostic Category 
Diagnostic category Number of 
cases 
B1  (Normal tissue) 85 
B2  (Benign lesion) 308 
B3  (Lesion of uncertain malignant potential) 51 
B4 (Suspicious) 5 
B5a (Malignant  ? in situ) 43 
B5b (Malignant- invasive) 145 
LB1 (No lymphoid tissue) 1 
LB2 (Benign lymphoid tissue) 22 
LB5 (Malignant, metastatic carcinoma or other) 5 
Other 29 
Total 694 
 
 
Table 5. Live reporting validation statistics. 
 Pathologist 1 Pathologist 2 Pathologist 3 All pathologists 
Technical failure 
rate 
0.7% 1.4% 1.0% 1.0% 
Complete 
concordance 
95.0% 96.2% 97.4% 96.2% 
Any observable 
difference 
5.0% 3.8% 2.6% 3.8% 
Complete clinical 
concordance 
99.3% 99.1% 98.5% 98.8% 
Clinically 
significant 
observable 
difference 
0.7% 0.9% 1.5% 1.2% 
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Table 6. Discordant cases from the live reporting phase of validation (V2) 
Specimen Digital Diagnosis Glass diagnosis Preferred diagnosis 
Core biopsy Grade 2 invasive ductal 
carcinoma 
Grade 3 invasive ductal 
carcinoma 
Glass 
Vacuum biopsy Benign phyllodes 
tumour 
Fibroadenoma with 
inflammation 
Glass 
Vacuum biopsy Columnar cell change Columnar cell change 
plus atypical 
intraductal 
proliferation 
Glass 
Vacuum biopsy Sclerosing adenosis Sclerosing adenosis, 
small focus ductal 
carcinoma in situ 
Glass 
Vacuum biopsy Microcysts Microcysts and 
weddelite calcification 
Glass 
Sentinel node Benign Isolated tumour cells Glass 
Vacuum biopsy Columnar cell change Columnar cell change, 
single focus atypical 
cells 
Glass 
Vacuum biopsy Small focus of ductal 
carcinoma in situ 
Benign Digital 
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Table7. Diagnostic confidence using digital and glass slides (0= not at all confident, 7 = very 
confident) 
 
 
 
 
 
  
 Digital slides Glass slides 
 Mean confidence 
(0-7) 
Range Mean confidence 
(0-7) 
Range 
Pathologist 1 6.70 4-7 6.80 4-7 
Pathologist 2 6.90 4-7 6.90 4-7 
Pathologist 3 6.79 0-7 6.99 6-7 
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